Compass Therapeutics, Inc. (CMPX) Company Overview

What does Compass Therapeutics do?

Compass Therapeutics, Inc. is a Boston-based, clinical-stage oncology biotechnology company listed on the Nasdaq Capital Market under CMPX. It has no approved medicine and develops antibody therapeutics intended to alter tumor blood-vessel formation and immune evasion. The corporate profile on the official investor-relations site describes a scientific focus on the relationship among angiogenesis, the immune system, and tumor growth.

Which biological problems does the pipeline target?

Compass uses three related approaches. First, tovecimig blocks DLL4 and VEGF-A to disrupt productive tumor angiogenesis. Second, CTX-8371 and CTX-10726 combine immune-checkpoint and angiogenesis targets in bispecific formats. Third, CTX-471 stimulates CD137, a co-stimulatory receptor on immune cells. The official pipeline page shows one late-stage program and three earlier clinical programs, making the company more diversified than a single-asset biotech but still highly dependent on tovecimig.

How could Compass Therapeutics make money?

Compass has no recurring commercial revenue. It spends on research, trials, manufacturing readiness, regulatory work, and commercial preparation, then could earn product sales after approval. It can also license geographic or development rights for upfront payments, milestones, and royalties. With no licensing revenue in FY2025 versus $0.85 million in FY2024, current financial statements mainly measure investment intensity and liquidity.

What is the path from science to revenue?

How do licensing obligations affect eventual margins?

Tovecimig was licensed from ABL Bio through TRIGR. Under the arrangements summarized in Compass's 2025 Form 10-K, ABL Bio received a $5.0 million upfront payment and a $6.0 million milestone payment and remains eligible for up to $96.0 million of oncology development and regulatory milestones, up to $303.0 million of oncology commercial milestones, and tiered single-digit royalties. That means gross product revenue would not translate one-for-one into Compass gross profit. Investors must model royalties, milestone timing, manufacturing cost, sales infrastructure, and any regional partner economics.

Which programs matter most to the CMPX story?

Tovecimig is the near-commercial asset and therefore dominates the current valuation narrative. The other programs matter because they can diversify clinical risk and show whether Compass's antibody design capabilities are repeatable. However, the scale of disclosed spending and the timing of milestones make the hierarchy clear: regulatory progress for tovecimig is the first-order driver; early efficacy for CTX-8371 and CTX-10726 is the next layer; CTX-471 and preclinical cell engagers are longer-duration options.

What did COMPANION-002 establish?

The randomized study enrolled 168 patients at 34 U.S. sites, assigning 111 to tovecimig plus paclitaxel and 57 to paclitaxel alone. The April 27, 2026 results initially reported a 17.1% response rate versus 5.3% for control and median PFS of 4.7 months versus 2.6 months, with a 0.44 hazard ratio and p<0.0001. The July presentation updated the independently reviewed response rate to 18.0%. Overall survival was difficult to interpret because 31 control patients, or 54% of that arm, crossed over to tovecimig.

Why is the crossover analysis both encouraging and risky?

Median overall survival was 8.9 months in the original combination arm and 9.4 months in the control arm, producing no significant intent-to-treat advantage. Yet control-arm patients who crossed over had median survival of 12.8 months versus 6.1 months for those who did not cross. This supports biological activity, but subset and post hoc analyses are less definitive than a clean randomized OS result. The FDA will need to decide whether response, PFS, crossover behavior, safety, and the unmet need together support approval.

What does Compass Therapeutics' latest quarter show?

The quarter ended March 31, 2026 confirms that Compass is still a development company: there was no product revenue, operating expenses were driven by R&D and corporate build-out, and interest income partially offset the loss. The latest Form 10-Q for Q1 2026 is most useful as a measure of cash runway, program prioritization, dilution, and the cost of approaching a BLA.

Where did research spending go?

How did Compass reach a near-commercial inflection point?

Compass's history is a sequence of financing, asset acquisition, and clinical de-risking. It began as an antibody-discovery business, became a public reporting company in 2020, added tovecimig through TRIGR, and concentrated capital on a randomized U.S. biliary tract cancer program.

1. 2014
   The operating business was founded, establishing the antibody-development platform and early immune-oncology programs.
2. 2018
   TRIGR entered the ABL Bio license for ABL001, later renamed CTX-009 and then tovecimig; this created the economic obligations that still shape the lead asset.
3. 2020
   A merger converted the private operating company into Compass Therapeutics, Inc., a public reporting company, broadening access to equity capital.
4. 2021
   Compass acquired TRIGR and assumed the tovecimig license; CMPX shares began trading on the Nasdaq Capital Market on November 2, 2021.
5. 2024
   COMPANION-002 completed enrollment with 168 patients, creating the pivotal dataset behind the current BLA strategy.
6. 2025
   The trial met its primary ORR endpoint, and a financing added approximately $129.4 million of net equity proceeds, extending the runway for regulatory and commercial work.
7. 2026
   PFS results strengthened the clinical case, tovecimig received Orphan Drug Designation, and management targeted an FDA meeting in Q3 and BLA submission in Q4.

What changed after the April 2026 readout?

Before the readout, Compass was primarily valued as a clinical-development company awaiting randomized secondary endpoints. After the PFS result, the operating agenda broadened to regulatory strategy, biologics manufacturing, market access, and a focused commercial build. The company's July 2026 corporate presentation furnished on Form 8-K stated a potential second-half 2027 approval and launch, while clearly treating that timing as forward-looking rather than assured.

Where does Compass compete, and what could differentiate it?

Compass competes on two levels. In biliary tract cancer, tovecimig faces chemotherapy and biomarker-specific medicines after first-line treatment. Across oncology, its pipeline competes for patients, investigators, capital, and eventual market access against larger checkpoint, angiogenesis, antibody-drug conjugate, and bispecific programs. The 2025 filing names AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Genentech/Roche, Johnson & Johnson, Merck, Novartis, Pfizer, and Sanofi among the better-funded competitors.

What is the most credible competitive advantage?

The strongest current advantage is not corporate scale; it is the combination of a differentiated DLL4 x VEGF-A mechanism, randomized evidence in a high-unmet-need setting, and a concentrated potential launch market. In the company's July 2026 materials, management estimated more than 15,000 U.S. patients per year could be eligible for tovecimig and identified roughly 250 high-volume BTC accounts. Those are company estimates rather than approved-label economics, but they illustrate why a small organization could potentially commercialize a specialty oncology product without a primary-care sales force.

How financially strong is Compass Therapeutics?

For a pre-revenue biotech, financial strength means liquidity relative to development and launch spending. At March 31, 2026, Compass held $55.2 million of cash and $139.5 million of marketable securities, totaling $195.0 million. Total liabilities were $18.7 million, with no conventional funded debt disclosed; the main long-term obligation was an operating lease.

What does the annual baseline say about burn and dilution?

Management stated in the Q1 2026 financial-results release that existing resources were expected to fund operations into 2028. That is a planning estimate, not a guarantee. A BLA, pre-approval manufacturing, launch inventory, sales hires, post-marketing commitments, and additional trials can accelerate cash use. Moreover, 180.1 million shares were outstanding at March 31, 2026 versus 137.8 million at December 31, 2024, showing that liquidity was achieved with substantial equity expansion.

Who owns CMPX stock, and why does governance matter?

Compass has one common-stock class with one vote per share, and no preferred shares were outstanding on the April 15, 2026 record date. Ownership is nevertheless concentrated among specialist biotechnology investors and directors connected to major holders. The latest 2026 definitive proxy statement reported 180.1 million common shares outstanding for ownership calculations as of March 31, 2026.

How should investors interpret the board structure?

The board is classified, with directors serving staggered terms, and maintains Audit, Compensation, and Nominating and Corporate Governance committees. The company states that the standing committees satisfy applicable Nasdaq and SEC independence standards. Governance documentation is available through the official governance portal. For a biotech, board expertise in clinical development, financing, commercialization, and transactions is especially material because strategic choices can include a self-launch, partnership, licensing deal, or sale.

What opportunities and risks could change the Compass story?

One regulatory decision could move Compass from pre-revenue development into commercial oncology. Clinical evidence, manufacturing, FDA interpretation, reimbursement, and physician adoption must all work, while tovecimig launch spending must not crowd out pipeline diversification.

Which milestones could create upside?

The October presentation will be a high-visibility scientific event; the official ESMO acceptance announcement states that the COMPANION-002 results will be presented as a Proffered Paper. Scientific visibility can support physician awareness, but conference acceptance does not substitute for regulatory approval.

Which risks are most material?

• Manufacturing failures or inspection deficiencies could delay approval or launch even if clinical efficacy is persuasive.
• Hypertension, proteinuria, cytopenias, and chemotherapy-related adverse events can affect benefit-risk and real-world use.
• New approved therapies for biomarker-defined BTC subsets or improved broad second-line regimens could narrow the market.
• Licensor milestones and royalties reduce product economics, while geographic exceptions limit full global capture.
• Recruiting patients for multiple parallel oncology trials can become slower or more expensive as competition increases.

What does CMPX mean for valuation and research?

A conventional revenue DCF is not appropriate because Compass has no approved product or stable margin. A risk-adjusted net present value model should treat each indication separately, using eligible patients, penetration, net price, royalties, operating costs, launch timing, exclusivity, taxes, and probability of technical and regulatory success. Add cash and securities, then deduct future burn, milestones, option dilution, and likely financing.

What is the key takeaway?

Compass has crossed from platform-stage promise into a near-commercial regulatory test. Tovecimig produced a clear response and progression benefit, and disclosed liquidity supports a filing alongside other antibodies. The story strengthens if FDA feedback validates the BLA route and early programs reproduce responses; it weakens if another pivotal study is required, launch costs exceed the runway, or follow-on assets fail.